<span item_type="fundamental" item_id="48845103636d75fac2a5afc8bbcafb63" counter_id="ST/US/CLYM" env="prod"></span><span item_type="announcement" item_id="548583879655494401" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.13.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Budoprutug</strong>: Direct research and development expenses for Budoprutug were $4.5 million for the three months ended June 30, 2025, and $10.6 million for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li><li><strong>CLYM116</strong>: Direct research and development expenses for CLYM116 were $145,000 for the three months ended June 30, 2025, and $9.3 million for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss was $8.7 million for the three months ended June 30, 2025, and $29.4 million for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses were $10.7 million for the three months ended June 30, 2025, and $33.7 million for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: Net cash used in operating activities was $26.6 million for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: Net cash used in investing activities was $38.0 million for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Research and Development Expenses</strong>: Total research and development expenses increased significantly to $23.9 million for the six months ended June 30, 2025, from $2.1 million for the same period in 2024, primarily due to increased costs for Budoprutug and CLYM116 programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Climb Bio, Inc. plans to advance Budoprutug in clinical trials for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with a focus on obtaining regulatory approvals and commercializing these therapies.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li><li><strong>Non-Core Business</strong>: The company is evaluating its Kv7 program, including seeking a partner for further development, after pausing further development of its Kv7 program in July 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li><li><strong>Priority</strong>: The company estimates that its cash, cash equivalents, and marketable securities will be sufficient to fund its planned operations through 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm"></span></li></ul>

Climb Bio | 10-Q: FY2025 Q2 EPS: USD -0.13